SASanofi India500674Dividend news update

Board declares interim dividend of Rs. 75 per share; approves Q3 and nine-month results

Sanofi India's board declared an interim dividend of Rs. 75/- per equity share (face value Rs. 10/-) for the financial year 2026.

By ScoutQuest · Thu 29 Oct 2026, 6:40 PM IST · 2 min read

Interim Dividend

Rs. 75/- per equity share (face value Rs. 10/-) for the financial year 2026

Record Date

5 November 2026

Results Approved

unaudited financial results for the quarter and nine months ended 30 September 2026

What the board approved

• An interim dividend of Rs. 75/- per equity share of face value Rs. 10/- each for the financial year 2026, to be paid within the stipulated timelines.
• Thursday, 5 November 2026 is fixed as the record date. Members on the Company's Register of Members on that date, and those appearing as beneficial owners with NSDL and CDSL as of that date, receive the dividend.
• The unaudited financial results for the quarter and nine months ended 30 September 2026, along with the limited review report of the statutory auditors.

The quarterly numbers (statement is presented in Rs. Million):

• Revenue from operations: 4,917 for the September 2026 quarter, against 4,754 in the September 2025 quarter.
• Profit for the period: 1,167, against 760 a year earlier.
• Profit before tax and exceptional items rose 22% to INR 158 crores, from INR 130 crores in the September 2025 quarter.
• Profit after tax growth of 54% for the quarter, as stated by the Managing Director.
• An exceptional item of ₹273 million relating to personnel separation costs was booked in the quarter and nine months ended 30 September 2026.

What the company said about the business

• The India business is described as being in momentum, with the diabetes portfolio growing in double digits quarter-on-quarter at a year-to-date level.
• The insulin portfolio extended its run with high single-digit growth in the quarter, and Sanofi is described as holding a market share of 55% in the diabetes injectable segment, with Lantus, Toujeo and Apidra leading and Soliqua also contributing.
• The public sector business grew strongly, helped by new accounts in innovative analogue segments.
• Export sales delivered double-digit growth.
• Partnership revenues in the Cardiovascular, Oral anti-Diabetes and Central Nervous System segments were broadly stable, with the company noting that continued focus is needed to strengthen performance.
• Operating expenses (employee cost plus other expenses) declined, which the company links to product mix, a one-off reversal of provisions and cost efficiencies.

How to read this as a shareholder

• The dividend is a cash payout decided by the board for this financial year; the record date decides who is entitled to it.
• Two things were announced together — a payout and the quarterly numbers — so the update is a mix of a corporate action and an earnings update.
• The profit figures include an exceptional charge for personnel separation costs, so the reported profit and the profit before exceptional items differ; both are shown in the statement.
• The results are unaudited and have been subjected to a limited review by the auditors, which is a lighter check than a full audit.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev